康希諾生物-B(06185.HK)附屬單針新冠疫苗量產上市
據內媒報道,康希諾生物-B(06185.HK)附屬上藥康希諾生產的新冠疫苗,今日(27日)在上海市寶山區舉行量產上市儀式,預期將大幅提升上海新冠疫苗接種的本地化可持續供應能力。
此次在上海量產上市的新冠疫苗名為「克威莎」,是目前國內獲准使用的7款新冠疫苗中唯一一款單針新冠疫苗,於2021年2月25日在國內獲批附條件上市,因一劑有效、14天快速形成保護的特點,能夠更快實現大規模接種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.